MX2023006445A - Composiciones y usos de estas para el tratamiento del síndrome de angelman. - Google Patents

Composiciones y usos de estas para el tratamiento del síndrome de angelman.

Info

Publication number
MX2023006445A
MX2023006445A MX2023006445A MX2023006445A MX2023006445A MX 2023006445 A MX2023006445 A MX 2023006445A MX 2023006445 A MX2023006445 A MX 2023006445A MX 2023006445 A MX2023006445 A MX 2023006445A MX 2023006445 A MX2023006445 A MX 2023006445A
Authority
MX
Mexico
Prior art keywords
angelman syndrome
compositions
treatment
ube3a
raav
Prior art date
Application number
MX2023006445A
Other languages
English (en)
Spanish (es)
Inventor
James M Wilson
Ralf Schmid
Justin Percival
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2023006445A publication Critical patent/MX2023006445A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2023006445A 2020-12-01 2021-12-01 Composiciones y usos de estas para el tratamiento del síndrome de angelman. MX2023006445A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119860P 2020-12-01 2020-12-01
US202163179807P 2021-04-26 2021-04-26
PCT/US2021/061346 WO2022119890A1 (en) 2020-12-01 2021-12-01 Compositions and uses thereof for treatment of angelman syndrome

Publications (1)

Publication Number Publication Date
MX2023006445A true MX2023006445A (es) 2023-08-10

Family

ID=80123326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006445A MX2023006445A (es) 2020-12-01 2021-12-01 Composiciones y usos de estas para el tratamiento del síndrome de angelman.

Country Status (9)

Country Link
US (1) US20230414785A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255500A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023551911A (cg-RX-API-DMAC7.html)
KR (1) KR20230128001A (cg-RX-API-DMAC7.html)
AU (1) AU2021392642A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200192A1 (cg-RX-API-DMAC7.html)
IL (1) IL303239A (cg-RX-API-DMAC7.html)
MX (1) MX2023006445A (cg-RX-API-DMAC7.html)
WO (1) WO2022119890A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240261438A1 (en) * 2023-02-08 2024-08-08 Ginkgo Bioworks, Inc. Gene therapy for angelman syndrome

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
HRP20181315T1 (hr) 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
EA037448B1 (ru) 2012-06-08 2021-03-30 Этрис Гмбх Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
US9567369B2 (en) 2012-08-03 2017-02-14 A.T. Still University Method of treating metastatic cancer
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
HUE055282T2 (hu) 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása
EP3387138B2 (en) 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
HRP20231451T1 (hr) * 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
US20210268072A1 (en) 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
CA3068304A1 (en) 2017-06-28 2019-01-03 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome
CN111936624A (zh) 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
TW202344691A (zh) 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
KR20210040358A (ko) * 2018-06-14 2021-04-13 오비드 테라퓨틱스 인크. 안젤만 증후군의 치료에서 mir-92a 또는 mir-145의 사용
MX2021007600A (es) 2018-12-21 2021-08-11 Univ Pennsylvania Composiciones para la reduccion de la expresion transgenica especifica de drg.
EP3941530A4 (en) * 2019-03-21 2022-12-14 PTC Therapeutics, Inc. ANGELMAN SYNDROME TREATMENT VECTOR AND PROCEDURES
WO2020223232A1 (en) * 2019-04-29 2020-11-05 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
EA202193214A1 (ru) * 2019-05-22 2022-03-14 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Гены ube3a и кассеты экспрессии и их использование
IT201900008877A1 (it) 2019-06-13 2020-12-13 Univ Bologna Alma Mater Studiorum Nuovi costrutti per terapia genica
JP2022552254A (ja) 2019-10-10 2022-12-15 アミカス セラピューティックス インコーポレイテッド バリアントigf2構築体
IL292382A (en) * 2019-10-22 2022-06-01 Applied Genetic Tech Corporation Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders
WO2021087282A1 (en) 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods

Also Published As

Publication number Publication date
AU2021392642A1 (en) 2023-06-22
CA3200192A1 (en) 2022-06-09
IL303239A (en) 2023-07-01
KR20230128001A (ko) 2023-09-01
JP2023551911A (ja) 2023-12-13
WO2022119890A9 (en) 2023-07-27
EP4255500A1 (en) 2023-10-11
WO2022119890A1 (en) 2022-06-09
US20230414785A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
MX2022001607A (es) Composiciones y metodos para tratar la psoriasis y la dermatitis atopica usando prevotella histicola.
MX2022008197A (es) Metodo para el tratamiento del sindrome de usher y composicion del mismo.
PH12022550399A1 (en) MTA-Cooperative PRMT5 Inhibitors
MX2022005236A (es) Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina.
AU2018268859A1 (en) Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
WO2017191274A3 (en) Rna encoding a therapeutic protein
ZA202300505B (en) Compositions useful for treatment of charcot-marie-tooth disease
MX2021013420A (es) Composiciones utiles en el tratamiento de leucodistrofia metacromatica.
PH12022550130A1 (en) Enzyme inhibitors
MX2023001564A (es) Terapias genicas para trastornos neurodegenerativos.
WO2022195074A3 (en) Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy
PH12022550124A1 (en) Enzyme inhibitors
EP4707400A3 (en) Gene therapies for lysosomal disorders
MX2022005670A (es) Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn.
WO2019222314A8 (en) Raav vectors encoding of lysosomal beta-galactosidase (glb1) and cathepsin a
CR20240097A (es) Malonamidas herbicidas
MX2020005673A (es) Terapia génica para mucopolisacaridosis iiib.
PH12022550118A1 (en) Enzyme inhibitors
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
WO2020014591A8 (en) Apmv and uses thereof for the treatment of cancer
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2020142740A8 (en) Treatment of sjogren's disease with nuclease fusion proteins
MX2023008801A (es) Composiciones y metodos para tratar angioedema hereditario.
MX2025004473A (es) Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
PH12020552172A1 (en) Cyclic dinucleotides as sting agonists